Basrobin1@gmail.com
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
8:05a ET 1/31/2024 - Globe Newswire
Xeriant Signs MOU with Innovative Materials Processor for NEXBOARD(TM)
Partnership is key step in Implementing Xeriant's Proprietary Manufacturing Process and Securing CertificationsGlobeNewswireJanuary 31, 2024
BOCA RATON, Fla., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Xeriant, Inc. (OTCQB: XERI) ("Xeriant" or "the Company"), a company dedicated to the discovery, development and commercialization of aerospace technologies and advanced materials, announced today that it has signed a Memorandum of Understanding ("MOU") with an industry-leading innovator in recycling, compounding and pelletizing systems for converting waste materials into useful eco-friendly products. The agreement formalizes the existing relationship with Xeriant, which began several months ago, and establishes a framework leading to a definitive agreement for an eventual acquisition. Xeriant will significantly benefit in several strategic areas critical to the success of NEXBOARD and future DUREVER(TM) products. Xeriant has limited its disclosure in this announcement because of the proprietary technology involved.
"There is great synergy between our companies. The partnership delivers decades of expertise and the specialized equipment and systems required for processing materials to manufacture NEXBOARD and creates a barrier to competition. Cost-effectively producing NEXBOARD is enabled by having access to abundant, clean and consistent source materials, which is also accomplished through this agreement," commented Xeriant CEO, Keith Duffy.
The holiday season is here, and with it, the opportunity to reflect on the past year's accomplishments and challenges.
We started 2023 with a concentrated program to strengthen our production silkworm strains with the goal of increasing their robustness and tolerance for the commercial production environment. We undertook this program because our study of our previous attempts to ramp up production indicated that our laboratory strains may have been overly inbred or otherwise lacked the necessary robustness to carry out our production objectives.
This process involved selective breeding over many generations and isolating target traits while crossbreeding with more robust specimens. The ultimate goal was to create two, and ultimately four, separate strains of our silkworm, which, when crossed with each other, would produce significant hybrid vigor. This program has been very successful.
That success, along with the items described below, has positioned us well for 2024. Over the past year, we have created nine new silkworm strains to improve robustness. We are now concentrating on six of those strains, half of which are ready or nearly ready for field trials. One of those strains is already homozygous for the spider silk transgene, and we expect two more strains to be homozygous within two more generations.
We performed an early field test with two of these strains, as described in a recent press release. The results greatly exceeded our expectations. This testing with a two-strain hybrid created the largest caterpillars and cocoons Kraig Labs has ever produced. As we look to the 2024 silk-producing season, these new lines will become the bedrock upon which future production is built. We have additional strains in earlier stages of development that we hope to roll out in the third or fourth quarter of 2024 for double hybrid production.
While our core focus remains on the immediate commercialization of existing spider silk technologies, our molecular biology team continues to work on the next generation of materials. This work continues to advance forward but is moving more slowly than we had hoped. This delay is primarily related to our transition to more advanced technology platforms. Our work is now focused on larger, more complex silk protein designs as well as newer splicing technologies that have challenged our team. We had hoped to announce the creation of a new transgenic in November, but we have not hit that mark. We will add additional resources to our molecular biology team in early 2024 to speed up this process. We remain confident in our ability to further improve our spider silks and obtain goals which we have not yet publicly announced. As new transgenics are produced and verified, we will continue to share those updates with you.
As I sit down to write this year in review update, I have just returned from a very successful trip to Vietnam. I come to you today re-invigorated by the exciting opportunities ahead for Kraig Labs, our shareholders, and spider silk. A recent small-scale test of changes in our production system was successful. In the process of that test, we also learned how we can improve our procedures and business model beyond mere silkworm robustness to achieve our production objectives. We have active negotiations in process with public and private sector actors, which would have been unimaginable six months ago.
I founded Kraig Labs with the vision of becoming a world leader in the bio-engineering of spider silk. Our team met that challenge by creating our silkworm-based spider silk production platform, by creating Dragon SilkTM, and now the six new production strains we created in 2023. Our core competency has been molecular biology. Our shortfall has been translating our successes in the laboratory to sericulture and production success outside of that environment.
Through our work at our subsidiary, Prodigy Textiles, we have come to better understand the global silk industrial base and the narrow pinch-points in silk manufacturing. Nearly all global silk production results from silkworm eggs produced in either India or China and then shipped worldwide. This is a matter of critical importance which directly affects the nature of sericulture as practiced in virtually all other countries. The breeding of silkworms and the production of eggs is a highly specialized and narrowly concentrated skill set that goes beyond hatching silkworms and rearing them for production.
In Vietnam, there has traditionally been little to no silkworm egg production for mass commercialization. The importance of mastering egg production cannot be overstated, and it is an area where our efforts were falling short. We are investing considerable resources to become world leaders in this field as well. While we have always done breeding and egg production in our laboratories, we found, through the school of hard knocks, that our skill sets in this area did not translate outside of the environmentally controlled lab.
Kraig Labs has now engaged leading experts from India to assess, train, and revamp our domestic and international operations to meet the exacting standards used in India's commercial silk operations. These leaders in their field, from the fastest-growing silk producer in the world, are now advising us on all aspects of our sericulture operations, from breeding and strain development to disease screening and management. We expect to bring them to our overseas operations in early 2024 to work hand in hand with our team as we drive toward our target of metric-ton spider silk production.
These experts have already brought much clarity to the hows and whys of past production shortcomings. While the robustness of our silkworms was a factor, it was not the only factor. With their help, we are now establishing control over those variables. My commitment to making Kraig Labs a world-class organization means having the absolute best people. Our team of consultants from India represents the out-and-out best of the best when it comes to metric-ton scale silk production.
With our new friends from India and the opportunities that lie before us, we plan to make 2024 the greatest year yet for Kraig Labs and the commercialization of spider silk. We are very excited to get to work in 2024, unlocking the potential of this enterprise. It is from that perspective that we look forward to the New Year and new horizons.
From our team at Kraig Labs, we hope your holiday season is spent with loved ones and filled with joy. We thank you for your continued support as we work to revolutionize the textile industry and deliver the incredible opportunities that await our spider silk.
Season's Greetings, Happy New Year, Merry Christmas, and Happy Hanukkah to all our shareholders and the world.
Kraig’s shares are currently traded OTC under the symbol KBLB. The company hopes to list them on Nasdaq or another national exchange under the same symbol.
Based in Michigan, Kraig Biocraft uses recombinant DNA technology to create high-strength fibers for the technical textile and specialty fiber sectors
Kraig Biocraft updates filing for proposed uplisting, $10M offering
Nov. 22, 2023 5:58 PM ETKraig Biocraft Laboratories, Inc. (KBLB)By: Val Brickates Kennedy, SA News Editor
Large yellow signboard on metal frame with the word IPO
ismagilov
Kraig Biocraft Laboratories (OTCQB:KBLB) has updated its filing with the SEC for a proposed $10M offering and uplisting to Nasdaq.
Kraig said in its latest filing that it was looking to offer 1.9M units in the range of $4.25 to $6.25, with an assumed price of $5.25. Each unit would consist of one common share plus one warrant to buy one common share for the assumed price of $5.25.
Underwriters would be granted a 45-day option to buy up to 286K additional shares and/or warrants. Maxim Group is serving as sole bookrunner.
SUBJECT TO COMPLETION
PRELIMINARY PROSPECTUS DATED November 22, 2023
KRAIG BIOCRAFT LABORATORIES, INC.
1,904,762 Units
Each Unit Consisting of One Share of Class A Common Stock One Warrant to Purchase One Share of Class A Common Stock
1,904,762 Shares of Class A Common Stock underlying the
Warrants
138,528 Representative Warrants
138,528 Shares of Class A Common Stock underlying the
Representative Warrants
This is a firm commitment underwritten public offering by Kraig Biocraft Laboratories, Inc., a Wyoming corporation (the
"Company") of 1,904,762 units (the "Units"), based on an assumed initial offering price of $5.25 per Unit, the midpoint of the anticipated price range of the Units. We anticipate a public offering price between $4.25 and $6.25 per Unit.
Each Unit consists of 1 share of our Class A common stock, no par value (the "Common Stock) and one warrant (a "Purchase Warrant") to purchase one share of our Common Stock at an exercise price of $5.25 per share (100% of the price of each Unit sold in this offering based on an assumed initial offering price of $5.25 per Unit, the midpoint of the anticipated price range). The Units have no stand-alone rights and will not be certificated or issued as stand-alone securities. The shares of Common Stock and Purchase Warrants comprising the Units are immediately separable and will be issued separately in this offering. Each Purchase Warrant offered hereby is immediately exercisable on the date of issuance and will expire five years from the date of issuance. The public offering price will be determined by us and Maxim Group LLC ("Maxim"), as representatives of the underwriters, taking into consideration several factors as described in "Underwriting - Determination of Offering Price", and will not be based upon the
price of our Common Stock on the ATCOR Marketalace
What a F👏 joke
All this is accomplished in an automotive-style, mass-production environment. NC homes are delivered to their building lots where final installation takes place.
From factory to move-in, most homes are completed in 2 to 8 days (depending on size and complexity) by NC factory install crews.
Next New Concept will use the proceeds of this offering for a U.S. base of operations and corporate headquarters. We maintain U.S. ownership of our technologies, patents, trademarks, product testing, and independent certifications. We license these to our foreign subsidiaries and draw ongoing management and licensing fees from them.
As majority owners, we control the distribution of profits. We are risk averse requiring our customers to provide down payments and necessary financial resources: cash, sovereign guarantees, and or collateral to fund their projects independently of Next New Concept.
UPDATE ON NC's AFRICAN MEGA-DEVELOPMENT; a $250+ MILLION PAYDAY FOR XERIANT'S NEXBOARD
"GREEN" BUILDING MATERIAL
https://www.equitynet.com/c/next-new-concept-inc
NC provides high-quality, sustainable, modular housing worldwide. With a 25,000-home, $3B, in-hand contract, ours is a path for rapid growth and global success.
Next New Concept (NC) is a U.S. holding company structured with its foreign subsidiaries to produce economical, scalable housing solutions. NC has collaborated with one of the largest private landowners in the Ivory Coast to build residential developments.
They have granted NC land valued at $33M to secure the project.
NC is working with U.S. International Development Finance Corporation (DFC) and banks to finalize a $60M working capital and a fixed asset credit line, including in-country manufacturing. Deliveries of homes to the job site begin Q2 2024.
NNCT homes incorporate sustainable materials, proprietary patents-pending structural aluminum framing and attractive, durable finishes, high-quality windows, doors, and appliances. Finished homes are turnkey and move-in ready.
The incentive to utilize the NC WHOLE HOUSE
Building System™ is NC's high production capacity of 400 homes per month. Our innovative technology and construction systems are designed for EASE of manufacture, SPEED of construction, and SUPERIOR
Pursuant to this prospectus, the selling shareholders identified herein (each a “Selling Shareholder” and, collectively, the “Selling Shareholders”) are offering on a resale basis, up to 306,124,163 shares of common stock, no par value per share (the “common stock”) of Kraig Biocraft Laboratories, Inc. (the “Company,” “Kraig,” “we,” “our” or “us”). These shares include: (i) 278,213,449 shares of common stock underlying secured convertible notes pursuant to that certain securities purchase agreement dated as of January 18, 2022 between the Company and Yorkville (the “2022 Yorkville Transaction”); (ii) 12,500,000 shares of common stock underlying a warrant issued pursuant to the 2022 Yorkville Transaction; (iii) 4,285,714 shares underlying a second warrant issued pursuant to the 2022 Yorkville Transaction; (iv) 8,000,000 shares of common stock underlying a warrant issued pursuant to the transactions contemplated by that certain securities purchase agreement dated as of March 26, 2021 between the Company and Yorkville (the “2021 Yorkville Transaction”); and (v) 3,125,000 shares of common stock underlying a warrant issued on December 11, 2020. We are not selling any shares under this prospectus, and we will not receive any proceeds from the sales of shares by the Selling Shareholders. We will, however, receive the exercise price of the Warrants, if and when such Warrants are exercised for cash by the holders of such Warrants.
The shares included in this prospectus may be offered and sold directly by the Selling Shareholders in accordance with one or more of the methods described in the “Plan of Distribution,” which begins on page 29 of this prospectus. To the extent the Selling Shareholders decide to sell their shares, we will not control or determine the price at which the shares are sold.
Our common stock is listed on OTCQB under the symbol “KBLB.” On September 8, 2023, the last reported sale price of our common stock was $0.0300 per share.
This offering will terminate on the earlier of (i) the date when all of the shares have been sold pursuant to this prospectus or Rule 144 under the Securities Act of 1933, as amended (the “Securities Act”), and (ii) the date that all of the securities may be sold pursuant to Rule 144 without volume or manner-of-sale restrictions, unless we terminate it earlier.
Investing in our securities involves a high degree of risk. You should carefully consider the risk factors described under the heading “Risk Factors” beginning on page 14 of this prospectus and under similar headings in any amendments or supplements before purchasing shares of our Common Stock.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
Scam scam scam
eVTOL aircraft, materials developer Xeriant files to raise $10M, uplist to Nasdaq
Jan. 19, 2023 5:32 PM ETXeriant, Inc. (XERI)EVTL, JOBY, LILM, EVEX, ACHRBy: Val Kennedy, SA News Editor1 Comment
IPO-Initial Public Offering
marrio31
Eco-friendly materials and eVTOL aircraft developer Xeriant (OTCQB:XERI) has filed to uplist its shares to Nasdaq and raise around $10M.
Xeriant didn't specify the terms of the proposed offering in its filing, but said in a filing fee schedule that it was looking to raise $10M The company is also planning to conduct a reverse stock split ahead of the transaction.
Xeriant hopes to list its shares on Nasdaq. Shares are currently traded OTC under the symbol XERI. Maxim Group is serving as lead bookrunner.
Based in Boca Raton, Fla., Xeriant acquires, develops and commercializes disruptive technologies, with a focus on eco-friendly advanced materials and next-generation aircraft. For the year ended June 30, Xeriant reported a net loss of $16M with no revenue.
Xeriant has a joint venture with Slovakian chemical company Movychem for the commercialization of Movychem's Retacell flame retardation technology. It has a second joint venture with XTI Aircraft for development of a six-seater eVTOL fixed-wing aircraft called the TriFan 600.
Other publicly traded eVTOL developers include Joby (JOBY), Eve (EVEX), Vertical Aerospace (EVTL), Archer Aviation (ACHR) and Lilium (LILM).
In October 2021, Xeriant said it was moving forward with plans to merge with XTI.
Now Read: BLDP, EH and ACHR among industrial movers
Based in Boca Raton, Fla., Xeriant acquires, develops and commercializes disruptive technologies, with a focus on eco-friendly advanced materials and next-generation aircraft. For the year ended June 30, Xeriant reported a net loss of $16M with no revenue.
Xeriant has a joint venture with Slovakian chemical company Movychem for the commercialization of Movychem's Retacell flame retardation technology. It has a second joint venture with XTI Aircraft for development of a six-seater eVTOL fixed-wing aircraft called the TriFan 600.
Other publicly traded eVTOL developers include Joby (JOBY), Eve (EVEX), Vertical Aerospace (EVTL), Archer Aviation (ACHR) and Lilium (LILM).
eVTOL aircraft, materials developer Xeriant files to raise $10M, uplist to Nasdaq
Jan. 19, 2023 5:32 PM ETXeriant, Inc. (XERI)EVTL, JOBY, LILM, EVEX, ACHRBy: Val Kennedy, SA News Editor
IPO-Initial Public Offering
marrio31
Eco-friendly materials and eVTOL aircraft developer Xeriant (OTCQB:XERI) has filed to uplist its shares to Nasdaq and raise around $10M.
Xeriant didn't specify the terms of the proposed offering in its filing, but said in a filing fee schedule that it was looking to raise $10M The company is also planning to conduct a reverse stock split ahead of the transaction.
Xeriant hopes to list its shares on Nasdaq. Shares are currently traded OTC under the symbol XERI. Maxim Group is serving as lead bookrunner.
Bioengineered silk producer Kraig Biocraft sets terms for $10M IPO, uplisting
May 26, 2022 7:21 PM ETKraig Biocraft Laboratories, Inc. (KBLB)By: Val Kennedy, SA News Editor1 Comment
Kraig Biocraft Laboratories (OTCQB:KBLB), a producer of bioengineered silk, has set terms for a $10M initial public offering which includes uplisting its shares to a national exchange.
KBLB said in a filing that it plans to offer 1.9M units at the assumed priced of $5.25 per unit, which is at the midpoint of its price range of $4.25 to $6.25 per unit. Each unit will consist of one share plus one warrant to buy one share.
Underwriters will be granted a 45-day option to buy up to 286K additional shares and/or warrants. Maxim Group is serving as sole bookrunner. The company hopes to list its shares on Nasdaq or another national exchange under the symbol KBLB.
KBLB is focused on producing high strength fibers for commercial applications using recombinant DNA technology. The company is currently using bioengineered silkworms to produce recombinant spider silk that can be used for apparel, textiles, medical implants, cosmetics and other purposes.
The industrial biotech company is operating in the red. For 2021, KBLB reported a net loss of $8M and no revenue. KBLB said it plans to use proceeds from the deal in part to expand its production operations in Vietnam.
KBLB shares are currently traded OTC under the symbol KBLB. As of Thursday evening, the company had a market capitalization of around $67M.
Bioengineered silk producer Kraig Biocraft sets terms for $10M IPO, uplisting
News is out IPO
Kblb S-1 is out
News out
Fake news fake news and more fake news
Today is the day
9.17% stake in naked brands
Streeterville Capital Reports in 13G
file:///var/mobile/Library/SMS/Attachments/20/00/465B39AD-2347-4AEA-8968-FA42DBD8B155/IMG_5945.PNG
$3.01?
Let’s start a class action lawsuit against them whoever is short selling this stock
10-Q out
If the company is worth billions and you try to tell me Kim can’t get $24 million from nobody
Thank you
Does anyone knows how many Outstanding shares?TRFN
I will send you a picture from TD AMERITRADE
Text me your telephone number I’ll send you a picture
$.12 is the low $.51 is the high